Skip to content
SitemapMIA Media2021-09-10T15:30:19+10:00
Pages
Posts by category
- Category: Forums
- Category: Treatment
- Category: Lab Life
- Category: Observership
- Category: Awareness
- Category: Careers
- Category: Education
- Category: Events
- Category: Fundraising
- Category: Partners
- Category: Patient Support
- Category: People
- Category: Research News
- Category: Research Projects
Papers
- Characterizing Chronic Cutaneous Immune-Related Adverse Events Following Immune Checkpoint Inhibitors.
- Erratum: First-Line Nivolumab Plus Relatlimab Versus Nivolumab Plus Ipilimumab in Advanced Melanoma: An Indirect Treatment Comparison Using RELATIVITY-047 and CheckMate 067 Trial Data.
- Association of inherited genetic variants with multiple primary melanoma.
- Safety and efficacy of immune checkpoint therapy for the treatment of patients with cardiac metastasis: a multicenter international retrospective study.
- Single-Cell Multi-Omics: Insights into Therapeutic Innovations to Advance Treatment in Cancer.
- Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61-20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial.
- Use of Patient Reported Outcome Measures (PROMs) in Clinical Care: A Community-Based Allied Health Setting.
- In vivo reflectance confocal microscopy role for early to advanced lentigo maligna melanoma spectrum: A systematic review and pooled analysis.
- Economic Evaluation of Inguinal Versus Ilio-inguinal Lymphadenectomy for Patients with Stage III Metastatic Melanoma to Groin Lymph Nodes: Evidence from the EAGLE FM Randomized Trial.
- Neoadjuvant triplet immune checkpoint blockade in newly diagnosed glioblastoma.
- Sociodemographic and health factors associated with genetic testing in Australia: insights from a cohort-based study of 45,061 participants.
- Reflectance confocal microscopy: Presurgical margin assessment improves lentigo maligna and lentigo maligna melanoma management.
- Clinical outcomes and management following progressive disease with anti-PD-(L)1 therapy in patients with advanced Merkel Cell Carcinoma.
- A scoping review of factors influencing the implementation of liquid biopsy for cancer care.
- Health-related Quality of Life and hospital costs of Finnish melanoma patients participating in the second Multicenter Selective Lymphadenectomy Trial (MSLT-II).
- Strategies to promote the completion of patient-reported outcome measures by culturally and linguistically diverse and Indigenous Peoples in clinical care settings: A systematic review.
- Prognostic and predictive value of metformin in the European Organisation for Research and Treatment of Cancer 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
- Response to han and liu.
- Multiomic profiling of checkpoint inhibitor-treated melanoma: Identifying predictors of response and resistance, and markers of biological discordance.
- Phase Ib Study of Immunocytokine Simlukafusp Alfa (FAP-IL2v) Combined with Pembrolizumab for Treatment of Advanced and/or Metastatic Melanoma.
- Adjuvant Pembrolizumab in Stage II Melanoma: Outcomes by Primary Tumor Location in the Randomized, Double-Blind, Phase III KEYNOTE-716 Trial.
- Outcomes With Radiation Therapy as Primary Treatment for Unresectable Cutaneous Head and Neck Squamous Cell Carcinoma.
- Mohs micrographic surgery for the treatment of invasive melanoma: A systematic review with meta-analyses.
- Quality and usability of photographs of skin conditions taken in emergency departments for dermatology consultation.
- Experience, knowledge, practices and attitudes of emergency department medical staff regarding teledermatology.
- Approaches to Surgical Management of Anorectal Melanoma in the Pre- and Post-Immunotherapy Eras.
- The tumor immune microenvironment in primary cutaneous melanoma.
- European consensus-based interdisciplinary guideline for melanoma. Part 1: Diagnostics - Update 2024.
- Cancer cells impair monocyte-mediated T cell stimulation to evade immunity.
- Real-World Melanoma Miss-Rate In An NHS Hospital Dermatology Service. A Retrospective Study.
- The impact of surgical margins in managing regional metastases in cutaneous squamous cell carcinoma of the head and neck.
- Harnessing Molecular Insights for Translational Impact: Highlights from the Special Issue Titled "New Insights in Translational Bioinformatics".
- Letter to Editor: Avoiding statistical pitfalls when assessing the performance of risk prediction nomograms.
- Neoadjuvant anti-PD-1 alone or in combination with anti-TIGIT or an oncolytic virus in resectable stage IIIB-D melanoma: a phase 1/2 trial.
- Sex differences in melanoma survival-a GEM study.
- Sentinel Node Biopsy in Melanoma Remains a Valuable Clinical Tool. Comment on Dixon et al. Primary Cutaneous Melanoma-Management in 2024. J. Clin. Med. 2024, 13, 1607.
- Approaches to Surgical Management of Anorectal Melanoma in the Pre- and Post-Immunotherapy Eras.
- Neoadjuvant or perioperative therapy for melanoma metastasis in clinical practice: an international survey.
- Treatment sequence with tebentafusp and immune checkpoint inhibitors in patients with metastatic uveal melanoma and metastatic GNA11/GNAQ mutant melanocytic tumors.
- X and Y Differences in Melanoma Survival Between the Sexes.
- ASO Author Reflections: Is Sentinel Node Biopsy Still of Value for Patients with High-Risk Primary Melanomas Eligible for Adjuvant Immunotherapy?
- Impact of alternative diagnostic labels for melanoma in situ on management choices and psychological outcomes: protocol for an online randomised study.
- Three-Year Overall Survival With Nivolumab Plus Relatlimab in Advanced Melanoma From RELATIVITY-047.
- Phase 1/2 Study of the Indoleamine 2,3-Dioxygenase 1 Inhibitor Linrodostat Mesylate Combined With Nivolumab or Nivolumab and Ipilimumab in Advanced Solid Tumors or Hematologic Malignancies.
- The Development and Evaluation of a Convolutional Neural Network for Cutaneous Melanoma Detection in Whole Slide Images.
- Risk of Death Due to Melanoma and Other Causes in Patients With Thin Cutaneous Melanomas.
- Incidental Disappearing Proficient Mis-Match Repair Colon Cancer in a Patient with Advanced Metastatic Melanoma and the Rare Complications of Immunotherapy.
- Clinical significance of intra-thoracic and intra-abdominal sentinel lymph nodes detected on lymphoscintigraphy in truncal melanoma patients.
- Outcomes following long-term disease control with immune checkpoint inhibitors in patients with advanced melanoma.
- Update of clinical practice guidelines for the management of patients with sarcoma.
- Survival Outcomes in Patients Undergoing Pelvic Exenteration for Pelvic Mucosal Melanomas: Retrospective Single Institution Australian Study.
- Adjuvant systemic therapy in melanoma: Relative versus absolute benefit; the number needed to treat (NNT) versus the number needed to harm (NNH)?
- Short-Term Effectiveness of a Stepped-Care Model to Address Fear of Cancer Recurrence in Patients With Early-Stage Melanoma.
- Editorial Expression of Concern: Temozolomide induces senescence but not apoptosis in human melanoma cells.
- Ipilimumab plus nivolumab versus nivolumab alone in patients with melanoma brain metastases (ABC): 7-year follow-up of a multicentre, open-label, randomised, phase 2 study.
- Patient and Staff Experiences of Embedding Electronic Patient Reported Outcome Measures for Distress Screening and Quality of Life Assessment, Into Routine Melanoma Care: A Mixed-Methods Study.
- Nivolumab (NIVO) plus relatlimab (RELA) vs. NIVO in previously untreated, metastatic, or unresectable melanoma (RELATIVITY-047): 3- year overall survival (OS) and melanoma-specific survival (MSS) results.
- 121MO Anti-IL-8 (BMS-986253) in combination with nivolumab (NIVO) plus ipilimumab (IPI) in patients (pts) with advanced melanoma: Final analysis from the randomized part 2 of the phase I/II CA027-002 study.
- Efficacy and safety of nivolumab + relatlimab (NIVO+RELA) versus nivolumab + ipilimuab (NIVO+IPI) in the first-line (1L) treatment of advanced melanoma: updated data from an indirect treatment comparison.
- Impact of an online risk prediction tool for sentinel node metastasis on clinical decision-making in melanoma care: A mixed methods study.
- Nivolumab vs. Placebo in the Adjuvant Treatment of Patients with Stage IIB/C Melanoma: 3-Year Results of the CheckMate 76K (CM 76K) Study.
- European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - Update 2024.
- The Impact of Preoperative Facial Nerve Weakness and Facial Nerve Outcomes in the Management of Patients With Parotid Metastases of Cutaneous Squamous Cell Carcinoma.
- Impact of personalized response-directed surgery and adjuvant therapy on survival after neoadjuvant immunotherapy in stage III melanoma: Comparison of 3-year data from PRADO and OpACIN-neo.
- Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant CPI in BRAF V600-mutated stage III/IV melanoma.
- Long-term Outcomes among Patients Who Respond within the First Year to Nivolumab plus Ipilimumab or Nivolumab Monotherapy: A Pooled Analysis in 935 Patients.
- An updated review of immune checkpoint inhibitors in cutaneous oncology: Beyond melanoma.
- Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up.
- In vivo reflectance confocal microscopy role for early to advanced lentigo maligna melanoma spectrum: A systematic review and pooled analysis.
- A comparison of isolated limb infusion/perfusion, immune checkpoint inhibitors, and intralesional therapy as first-line treatment for patients with melanoma in-transit metastases
- DNA Methylation Classes of Stage II and III Primary Melanomas and Their Clinical and Prognostic Significance.
- Pooled Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone in Patients With Advanced Melanoma.
- BET inhibition sensitizes innate checkpoint inhibitor resistant melanoma to anti-CTLA-4 treatment.
- Uptake of health economic evaluations alongside clinical trials in Australia: an observational study.
- Acceptability and timing considerations when administering patient-reported outcome measures (PROMs) among people with chronic health conditions who are culturally and linguistically diverse (CALD): a qualitative study protocol.
- The effect of a single dose of nivolumab prior to isolated limb perfusion for patients with in-transit melanoma metastases: An interim analysis of a phase Ib/II randomized double-blind placebo-controlled trial (NivoILP trial).
- Quality of life outcomes in patients receiving dental implants in vascularised bone flaps for mandibular reconstruction.
- Anti-PD-1 alone or in combination with anti-CTLA-4 for advanced melanoma patients with liver metastases.
- Merkel-cell carcinoma: ESMO-EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up.
- Full-body skin examination in screening for cutaneous malignancy: a focus on concealed sites and the practices of Australian dermatologists.
- Neoadjuvant Triplet Immune Checkpoint Blockade in Newly Diagnosed Glioblastoma.
- Interferon-gamma signature as prognostic and predictive marker in macroscopic stage III melanoma.
- Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis
- Single-Cell Informatics for Tumor Microenvironment and Immunotherapy.
- Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease.
- Understanding the Tumor Microenvironment in Melanoma Patients with In-Transit Metastases and Its Impacts on Immune Checkpoint Immunotherapy Responses.
- The Impact of Next-generation Sequencing on Interobserver Agreement and Diagnostic Accuracy of Desmoplastic Melanocytic Neoplasms
- Stroma-infiltrating T cell spatiotypes define immunotherapy outcomes in adolescent and young adult patients with melanoma
- Cancer in general practice research priorities in Australia.
- Development and validation of a novel model to predict recurrence-free survival and melanoma-specific survival after sentinel lymph node biopsy in patients with melanoma: an international, retrospective, multicentre analysis.
- Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator
- ASO Author Reflections: Lymphoedema Related to Inguinal and Ilioinguinal Lymphadenectomy for Melanoma.
- BRAF Mutated and Morphologically Spitzoid Tumors, a Subgroup of Melanocytic Neoplasms Difficult to Distinguish From True Spitz Neoplasms.
- Cancer in general practice research priorities in Australia.
- Neo-Adjuvant Therapy for Metastatic Melanoma.
- POLARIS: A phase 2 trial of encorafenib plus binimetinib evaluating high-dose and standard-dose regimens in patients with BRAF V600-mutant melanoma with brain metastasis.
- Leg Lymphoedema After Inguinal and Ilio-Inguinal Lymphadenectomy for Melanoma: Results from a Prospective, Randomised Trial.
- Real-world health-related quality of life outcomes for patients with resected stage III/IV melanoma treated with adjuvant anti-PD1 therapy.
- Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma: Outcomes in histopathologic subgroups from the randomized, double-blind, phase 3 KEYNOTE-716 trial.
- Pembrolizumab Versus Placebo as Adjuvant Therapy in Resected Stage IIB or IIC Melanoma: Final Analysis of Distant Metastasis-Free Survival in the Phase III KEYNOTE-716 Study.
- Technical considerations for isolated limb perfusion: A consensus paper.
- Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma
- Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.
- International expert recommendations on image acquisition for in vivo reflectance confocal microscopy of cutaneous tumors.
- Prognostic and predictive biomarkers in head and neck cancer: something old, something new, something borrowed, something blue and a sixpence in your shoe.
- Transmission and Non-transmission of Melanoma From Deceased Solid Organ Donors to Transplant Recipients: Risks and Missed Opportunities.
- PKC-independent PI3K signalling diminishes PKC inhibitor sensitivity in uveal melanoma.
- Minimum labelling requirements for dermatology artificial intelligence-based Software as Medical Device (SaMD): A consensus statement.
- Plain language summary of the CheckMate 76K study results: nivolumab given after stage 2B/2C melanoma is removed by surgery.
- The difficulty with measuring the largest melanoma tumour diameter in sentinel lymph nodes.
- Implementation considerations for risk-tailored cancer screening in the population: A scoping review
- Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study.
- Commentary: Real-world post-deployment performance of a novel machine learning-based digital health technology for skin lesion assessment and suggestions for post-market surveillance
- A review of skin cancer primary prevention activities in primary care settings.
- Predicting Recurrence-Free and Overall Survival for Patients With Stage II Melanoma: The MIA Calculator.
- Health Economic Consequences Associated With COVID-19-Related Delay in Melanoma Diagnosis in Europe.
- Smoking Status and Survival in Patients With Early-Stage Primary Cutaneous Melanoma.
- Pathology: the narrative continues.
- Synchronous collision metastasis of melanoma and squamous cell carcinoma in a parotid lymph node: a very rare occurrence and literature review.
- Prognostic and predictive value of non-steroidal anti-inflammatory drugs in the EORTC 1325/KEYNOTE-054 phase III trial of pembrolizumab versus placebo in resected high-risk stage III melanoma.
- Cutaneous malignancies in chronic lymphocytic leukemia.
- Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series.
- Rethinking the urgency priority system in round hole detachments, which should be done first? Macula on or macula off.
- Associations between patient-level health literacy and diagnostic time intervals for head and neck cancer: A prospective cohort study.
- Author Correction: Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial.
- Implementing systematic melanoma risk assessment and risk-tailored surveillance in a skin cancer focussed dermatology clinic: A qualitative study of feasibility and acceptability to patients and clinic staff.
- Prognostic and predictive biomarkers in head and neck cancer: something old, something new, something borrowed, something blue and a sixpence in your shoe
- Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma.
- European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma. Part 1: Diagnostics and prevention-Update 2023.
- Implementing structured pathology reporting protocol for non-melanocytic skin cancers: practical considerations.
- Perspectives in Melanoma: meeting report from the Melanoma Bridge (December 1st-3rd, 2022-Naples, Italy).
- Looking beyond workforce parity: addressing gender inequity in pathology.
- Cutaneous melanoma
- Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors
- Acceptability of risk-tailored cancer screening among Australian GPs: a qualitative study.
- Multiomics analysis reveals a Type III driven immune response in immunotherapy-induced toxicity in melanoma and identifies potential new therapeutic targets.
- Efficacy of immune checkpoint inhibitors for the treatment of advanced melanoma in patients with concomitant chronic lymphocytic leukemia.
- Delphi Consensus Among International Experts on the Diagnosis, Management, and Surveillance for Lentigo Maligna.
- The association of dermatologist demographic density with melanoma survival in New South Wales, Australia.
- Preferences for Adjuvant Immunotherapy in Adults with Resected Stage III Melanoma-A Discrete Choice Experiment.
- Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma.
- Inter-rater concordance of basal cell carcinoma subtypes: influences on reporting format and opportunities for further classification modifications.
- Melanoma In Situ—Getting the Diagnosis and Prognosis Right.
- Health-related quality of life in patients with melanoma brain metastases treated with immunotherapy.
- Modeling Methods in Craniofacial Virtual Surgical Planning.
- Epidemiology, staging and management of mucosal melanoma of the head and neck: a narrative review.
- Definitive treatment with PD-1 blockade and radiation therapy of unresected primary desmoplastic melanoma of the nose.
- Reply to: 'Melanoma diagnosis at a specialist dermatology practice without the use of photographic surveillance'.
- Molecular and clinical correlates of HER3 expression highlights its potential role as a therapeutic target in melanoma.
- Neoadjuvant immunotherapy for melanoma is now ready for clinical practice.
- Adjuvant therapy for stage II melanoma: the need for further studies.
- Regarding: Predicting Regional Lymph Node Recurrence in The Modern Age of Tumor-Positive Sentinel Node Melanoma.
- ASO Author Reflections: The Clinical Relevance of Sentinel Nodes in Minor Lymph Node Fields Such as the Triangular Intermuscular Space in Patients with Melanoma.
- Systemic LRG1 expression in melanoma is associated with disease progression and recurrence.
- Comparing Genomic Landscapes of Oral and Cutaneous Squamous Cell Carcinoma of the Head and Neck: Quest for Novel Diagnostic Markers.
- Baseline ultrasound and FDG-PET/CT imaging in Merkel cell carcinoma.
- ASO Visual Abstract: Prognostic Significance and Management of Sentinel Nodes in the Triangular Intermuscular Space of Patients with Melanoma.
- Study protocol for a randomised controlled trial to evaluate the use of melanoma surveillance photography to the Improve early detection of MelanomA in ultra-hiGh and high-risk patiEnts (the IMAGE trial).
- Chemotherapy in Cutaneous Melanoma: Is There Still a Role?
- Time to reconsider the role of sentinel lymph node biopsy in melanoma
- Adjuvant radiotherapy after salvage surgery for melanoma recurrence in a node field following a previous lymph node dissection.
- Measuring the quality of skin cancer management in primary care: A scoping review.
- Human Genetics Society of Australasia Position Statement: Use of Polygenic Scores in Clinical Practice and Population Health. Twin Res Hum Genet.
- Junctional Nevus and Early Melanoma on Sun-Damaged Skin of the Head/Neck: a Clinico-Pathologic Challenge.
- Risk of developing a second primary melanoma after a first primary melanoma in a population-based Australian cohort.
- Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma.
- Health-related quality of life with nivolumab plus Relatlimab versus nivolumab monotherapy in patients with previously untreated unresectable or metastatic melanoma: RELATIVITY-047 trial.
- Role of reflectance confocal microscopy for in vivo investigation of oral disorders: White, red and pigmented lesions.
- The molecular and functional landscape of resistance to immune checkpoint blockade in melanoma.
- REPLY to MS#JAAD-D-23-00002R1.
- Has the advent of modern adjuvant systemic therapy for melanoma rendered sentinel node biopsy unnecessary?
- Spatial mapping reveals granuloma diversity and histopathological superstructure in human tuberculosis.
- IFN-γ signature enables selection of neoadjuvant treatment in patients with stage III melanoma.
- Lentigo maligna/lentigo maligna melanoma in young patients in Australian tertiary centres.
- Efficacy of ipilimumab 3mn/kg following progression on low-dose ipilimumab in metastatic melanoma.
- Rare immune-related adverse events in patients with melanoma: incidence, spectrum, and clinical presentations.
- Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery.
- MC1R 'r' allele does not increase melanoma risk in MITF E318K carriers.
- Melanotransferrin Functions as a Pro-Oncogenic WNT Agonist: A Yin-Yang Relationship in Melanoma with the WNT Antagonist and Metastasis Suppressor, NDRG1.
- Nicotinamide for Skin-Cancer Chemoprevention in Transplant Recipients.
- Common toxicities associated with immune checkpoint inhibitors and targeted therapy in the treatment of melanoma: A systematic scoping review
- Clinical features and outcomes of cardiac involvement in patients with cancer treated with immune checkpoint inhibitors.
- In vivo reflectance confocal microscopy can detect the invasive component of lentigo maligna melanoma: Prospective analysis and case-control study.
- A sheep in wolf's clothing: Agminated blue naevi masquerading as in-transit melanoma metastases.
- Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey.
- Case series: Immune checkpoint inhibitor-induced transverse myelitis.
- Reply to A. Mangla and E. Hindié.
- Intratumoral CD16+ macrophages are associated with clinical outcomes of patients with metastatic melanoma treated with combination anti-PD-1 and anti-CTLA-4 therapy.
- Longitudinal trajectory of quality of life for patients with melanoma brain metastases: A secondary analysis from a whole brain radiotherapy randomized clinical trial.
- Nivolumab and Relatlimab in Patients With Advanced Melanoma That Had Progressed on Anti–Programmed Death-1/Programmed Death Ligand 1 Therapy: Results From the Phase I/IIa RELATIVITY-020 Trial
- Efficacy and toxicity of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.
- Plain Language Summary - Development and validation of risk calculators for people with "thin" melanomas on their skin to predict the likelihood that their cancer will return.
- Author Correction: Reversal of pre-existing NGFR-driven tumor and immune therapy resistance.
- Lichen sclerosus and immune checkpoint inhibitors: A case and review of the literature.
- Clinical Features Associated with Outcomes and Biomarker Analysis of Dabrafenib plus Trametinib Treatment in Patients with BRAF-Mutant Melanoma Brain Metastases.
- IFNγ signaling sensitizes melanoma cells to BH3 Mimetics.
- ASO Visual Abstract: Is a History of Optimal Staging by SLNB in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
- Durability of response to immune checkpoint inhibitors in metastatic Merkel cell carcinoma after treatment cessation.
- Association of Germline Variants in Telomere Maintenance Genes (POT1, TERF2IP, ACD, TERT) with Spitzoid Morphology in Familial Melanoma: A Multi-Center Case Series.
- Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials.
- Genetics and Genomics of Melanoma: Current Progress and Future Directions.
- Interobserver agreement in the histopathological classification of desmoplastic melanomas
- Neo-Adjuvant Immunotherapy emerges as best medical practice and will be the new standard of care for macroscopic stage III Melanoma.
- Author Correction: Androgen receptor blockade promotes response to BRAF/MEK-targeted therapy.
- Biology and genetics of acquired and congenital melanocytic naevi
- A phase I trial of LXS196, a protein kinase C (PKC) inhibitor, for metastatic uveal melanoma.
- Genomic profiling of metastatic basal cell carcinoma reveals candidate drivers of disease and therapeutic targets.
- Alternatives and Reduced need for Sentinel Lymph Node Biopsy (SLNB) Staging for Melanoma
- Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma
- Representativeness of initial skin biopsies showing pure desmoplastic melanoma: implications for management
- Management of basal cell carcinoma with pulmonary metastasis.
- Neoadjuvant Relatlimab and Nivolumab for Resectable Melanoma.
- Revision of the Melanocytic Pathology Assessment Tool and Hierarchy for Diagnosis Classification Schema for Melanocytic Lesions: A Consensus Statement
- Interobserver agreement in the histopathological classification of desmoplastic melanomas.
- Hypercalcaemia secondary to hypophysitis and cortisol deficiency: another immunotherapy-related adverse event.
- Views of the Australian public on the delivery of risk-stratified cancer screening in the population: a qualitative study.
- Biology and genetics of acquired and congenital melanocytic naevi.
- Diagnostic biopsies of suspected skin cancer in general practice from 2010 to 2017 in Victoria, Australia
- Embedding electronic patient-reported outcome measures into routine care for patients with stage III MELanoma (ePROMs-MEL): protocol for a prospective, longitudinal, mixed-methods pilot study.
- Perspectives and Experiences of Patient-Led Melanoma Surveillance Using Digital Technologies From Clinicians Involved in the MEL-SELF Pilot Randomized Controlled Trial: Qualitative Interview Study
- Talimogene Laherparepvec in Combination with Immunotherapy, A Viable Option?
- Melanomas in children and adolescents: clinicopathologic features and survival outcomes.
- Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma.
- Clinical features associated with outcomes and biomarker analysis of dabrafenib plus trametinib treatment in patients with BRAF-mutant melanoma brain metastases.
- Incorporating carbon into health care: adding carbon emissions to health technology assessments.
- Prognostic Significance and Management of Sentinel Nodes in the Triangular Intermuscular Space of Patients with Melanoma.
- Talimogene laherparepvec monotherapy for head and neck melanoma patients.
- Genomic and proteomic findings in early melanoma and opportunities for early diagnosis.
- Reflectance confocal microscopy in Australia: Perspectives on barriers to implementation and uptake.
- Five-year survival and clinical correlates among patients with advanced non-small cell lung cancer, melanoma and renal cell carcinoma treated with immune check-point inhibitors in Australian tertiary oncology centres.
- The effect of organ-specific tumor microenvironments on response patterns to immunotherapy.
- Informing a position statement on the use of artificial intelligence in dermatology in Australia.
- BRAF inhibitor cessation prior to disease progression in metastatic melanoma: long term outcomes.
- Toripalimab vs High-Dose Interferon-α2b as Adjuvant Therapy for Resected Mucosal Melanoma.
- Which strategies support the effective use of clinical practice guidelines and clinical quality registry data to inform health service delivery? A systematic review.
- Phase 1b Study of Cobimetinib Plus Atezolizumab in Patients with Advanced BRAFV600 Wild-Type Melanoma Progressing on Prior Anti–Programmed Death-1 Therapy.
- Dataset for the Reporting of Merkel Cell Carcinoma: Recommendations From the International Collaboration on Cancer Reporting (ICCR).
- Utility of next generation sequencing for differentiating malignant PEComa from metastatic melanoma.
- ASO Visual Abstract: Predictors of Sentinel Lymph Node Metastasis in Patients with Thin Melanoma-An International Multi-institutional Collaboration.
- Tertiary lymphoid structures accompanied by fibrillary matrix morphology impact anti-tumor immunity in basal cell carcinomas.
- Combination of the STING Agonist MIW815 and PD-1 Inhibitor Spartalizumab in Advanced/Metastatic Solid Tumors or Lymphomas: An Open-label, Multicenter, Phase Ib Study.
- Discussion of costs and financial burden in clinical practice: A survey of medical oncologists in Australia.
- Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, phase 3 trial.
- Clinical Management of Melanocytic Tumours of Uncertain Malignant Potential (MelTUMPs), including Melanocytomas: A Systematic Review and Meta-Analysis.
- Motivations and Barriers to Participation in a Randomized Trial on Melanoma Genomic Risk: A Mixed-Methods Analysis.
- Real-world outcomes with ipilimumab and nivolumab in advanced melanoma: a multicentre retrospective study.
- Causes, consequences and clinical significance of aneuploidy across melanoma subtypes.
- Is a History of Optimal Staging by Sentinel Lymph Node Biopsy in the Era Prior to Adjuvant Therapy Associated with Improved Outcome Once Melanoma Patients have Progressed to Advanced Disease?
- Exploring the Integration of Environmental Impacts in the Cost Analysis of the Pilot MEL-SELF Trial of Patient-Led Melanoma Surveillance.
- Adjuvant pembrolizumab versus placebo in resected high-risk stage II melanoma: Health-related quality of life from the randomized phase 3 KEYNOTE-716 study.
- Metastasizing and non-metastasizing thick melanoma: clinicopathological predictors and molecular profiling.
- Factors influencing acceptance, adoption and adherence to sentinel node biopsy recommendations in the Australian Melanoma Management Guidelines: a qualitative study using an implementation science framework.
- Causes, consequences and clinical significance of aneuploidy across melanoma subtypes.
- Obesity is associated with altered tumor metabolism in metastatic melanoma.
- Hypoxia controls the glycome signature and galectin-8 - ligand axis to promote pro-tumorigenic properties of metastatic melanoma.
- Adjuvant Therapy of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Patients With Resected Stage IIIB-D or Stage IV Melanoma (CheckMate 915).
- Communicating Personal Melanoma Polygenic Risk Information: Participants’ Experiences of Genetic Counseling in a Community-Based Study.
- Validation of self-reported sun exposure against electronic ultraviolet radiation dosimeters.
- Recursive Partitioning to Determine Order of Significance of Regional Metastasis Characteristics in Head and Neck Cutaneous Squamous Cell Carcinoma.
- Neurological adverse effects associated with anti-PD1 antibodies alone or in combination with ipilimumab: a multicenter case series.
- Characteristics of immune checkpoint inhibitor-induced encephalitis and comparison with HSV-1 and anti-LGI1 encephalitis: A retrospective multicentre cohort study.
- Feasibility, acceptability, and utility of a nurse-led survivorship program for people with metastatic melanoma (MELCARE).
- Navigating the cellular landscape in tissue: Recent advances in defining the pathogenesis of human disease.
- Comparative genomics provides etiological and biological insights into melanoma subtypes
- Unveiling the tumor immune microenvironment of organ-specific melanoma metastatic sites.
- Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma.
- In vivo tumor immune microenvironment phenotypes correlate with inflammation and vasculature to predict immunotherapy response.
- Views of the Australian public on the delivery of risk-stratified cancer screening in the population: a qualitative study.
- Higher polygenic risk for melanoma is associated with improved survival in a high ultraviolet radiation setting.
- Assessing the value of precision medicine health technologies to detect and manage melanoma.
- Utility of optical coherence tomography in basal cell naevus syndrome: A case report
- Diet-driven microbial ecology underpins associations between cancer immunotherapy outcomes and the gut microbiome.
- Developing an Australian Melanoma Clinical Outcomes Registry (MelCOR): a protocol paper.
- Survival outcomes of perineural spread in head and neck cutaneous squamous cell carcinoma.
- KEYNOTE - D36: personalized immunotherapy with a neoepitope vaccine, EVX-01 and pembrolizumab in advanced melanoma.
- High-dimensional and spatial analysis reveals immune landscape dependent progression in cutaneous squamous cell carcinoma
- Sentinel node biopsy: linchpin of melanoma management.
- Response to 'Multicentre Selective Lymphadenectomy Trial 1: key primary data remain unavailable.
- Neoadjuvant nivolumab + T-VEC combination therapy for resectable early stage or metastatic (IIIB-IVM1a) melanoma with injectable disease: study protocol of the NIVEC trial.
- Whole genome analysis reveals the genomic complexity in metastatic cutaneous squamous cell carcinoma.
- Diagnosis and treatment of Merkel cell carcinoma: European consensus-based interdisciplinary guideline - Update 2022.
- Benchmarking Survival Outcomes Following Surgical Management of pT3 and pT4 Cutaneous Squamous Cell Carcinoma of the Head and Neck.
- Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations.
- Phase Ib/II Trial of Ribociclib in Combination with Binimetinib in Patients with NRAS-mutant Melanoma.
- Protein-based classification of melanoma differentiation subtypes.
- Re-induction ipilimumab following acquired resistance to combination ipilimumab and anti-PD-1 therapy.
- MHC Class I Deficiency in Solid Tumors and Therapeutic Strategies to Overcome It
- Outcomes after definitive treatment for head and neck angiosarcoma.
- The role of regional chemotherapy for advanced limb melanoma in the era of potentially effective systemic therapies.
- Changes in sun protection behaviours, sun exposure and shade availability among adults, children and adolescents in New South Wales, 2003-2016.
- Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma.
- Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells.
- Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.
- A survey of surgical management of the sentinel node positive melanoma patient in the post-MSLT2 era.
- Impact of Next-generation Sequencing on Interobserver Agreement and Diagnosis of Spitzoid Neoplasms.
- Assessing the Potential for Patient-led Surveillance After Treatment of Localized Melanoma (MEL-SELF): A Pilot Randomized Clinical Trial.
- Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma.
- Adaptive designs for clinical trials have potential advantages, but statistical challenges lurk!
- Multi-trait genetic analysis identifies auto-immune loci associated with cutaneous melanoma.
- KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.
- Optical coherence tomography features of a tumour of the follicular infundibulum.
- Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside.
- Case report of a challenging medium-sized congenital melanocytic nevus (CMN): Highlighting a role for reflectance confocal microscopy (RCM) for evaluating changing CMN in children.
- Association Between Melanoma Detected During Routine Skin Checks and Mortality.
- Complex melanoma of the scalp: Diagnosis and management aided by confocal microscopy.
- Review BRAF inhibition and the spectrum of granulomatous reactions.
- Antitumor Activity of Ipilimumab or BRAF ± MEK Inhibition After Pembrolizumab in Patients With Advanced Melanoma: Analysis from KEYNOTE-006.
- Repurposing Melanoma Chemotherapy to Activate Inflammasomes in the Treatment of BRAF/MAPK Inhibitor Resistant Melanoma.
- Acute bilateral phrenic nerve neuropathy causing hypercapnic respiratory associated with checkpoint inhibitor immunotherapy.
- Grade 4 Neutropenia Secondary to Immune Checkpoint Inhibition - A Descriptive Observational Retrospective Multicenter Analysis.
- High-Dimensional Single-Cell Transcriptomics in Melanoma and Cancer Immunotherapy
- Combined presentation and immunogenicity analysis reveals a recurrent RAS.Q61K neoantigen in melanoma.
- Interventions to Increase Sunscreen Use in Adults: A Review of the Literature.
- Immune checkpoint inhibitors in patients with pre-existing psoriasis: safety and efficacy
- Melanoma brain metastases that progress on BRAF-MEK inhibitors demonstrate resistance to ipilimumab-nivolumab that is associated with the Innate PD-1 Resistance Signature (IPRES).
- Road to Metastasis: The TWEAK Pathway as a Discriminant between Metastasizing and Non-Metastasizing Thick Melanomas
- Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006.
- Irregular Sleep/Wake Patterns Are Associated With Reduced Quality of Life in Post-treatment Cancer Patients: A Study Across Three Cancer Cohorts
- A practical guide on the use of Imiquimod cream for Lentigo Maligna.
- Interleukin-6 blockade for prophylaxis and management of immune-related adverse events in cancer immunotherapy.
- Immune checkpoint inhibitors in melanoma
- Adjuvant immunotherapy recommendations for stage III melanoma: physician and nurse interviews.
- PARP Inhibitors in Melanoma-An Expanding Therapeutic Option?
- Skin cancer classification via convolutional neural networks: systematic review of studies involving human experts.
- Position statement on classification of basal cell carcinomas. Part 1: unsupervised clustering of experts as a way to build an operational classification of advanced basal cell carcinoma based on pattern recognition.
- Position statement on classification of basal cell carcinomas. Part 2: EADO proposal for new operational staging system adapted to basal cell carcinomas.
- Metastatic acral melanoma treatment outcomes: a systematic review and meta-analysis.
- Cutaneous clear cell sarcoma with an epidermal component mimicking melanoma.
- Strengthening melanoma prevention and early detection among people with type 2 diabetes.
- A survey of surgical management of the sentinel node positive melanoma patient in the post-MSLT2 era.
- TMB and Inflammatory Gene Expression Associated With Clinical Outcomes Following Immunotherapy in Advanced Melanoma
- Residual melanoma in wide local excision specimens after 'complete' excision of primary cutaneous in situ and invasive melanomas.
- Impact of personal genomic risk information on melanoma prevention behaviors and psychological outcomes: a randomized controlled trial
- The concepts of rechallenge and retreatment with immune checkpoint blockade in melanoma patients
- Early use of high-dose-glucocorticoid for the management of irAE is associated with poorer survival in patients with advanced melanoma treated with anti-PD-1 monotherapy
- Survival Outcomes of Salvage Metastasectomy after Failure of Modern-Era Systemic Therapy for Melanoma
- ASO Author Reflections: Surgical Resection May Improve the Outcome for Patients with Residual Metastatic Melanoma When Modern Systemic Therapies Have Not Achieved Complete Disease Control
- In Sentinel Node-Positive Melanoma Patients, Does Omission of Completion Lymph Node Dissection Make More Intensive Follow-Up Necessary, and Does Adjuvant Systemic Therapy Permit Less Intensive Follow-Up?
- Confocal microscopy, dermoscopy, and histopathology features of atypical intraepidermal melanocytic proliferations associated with evolution to melanoma in situ
- Correction to: Histological regression in melanoma: impact on sentinel lymph node status and survival.
- Survival Outcomes of Salvage Metastasectomy After Failure of Modern-Era Systemic Therapy for Melanoma
- Ipilimumab versus ipilimumab plus anti-PD-1 for metastatic melanoma - Authors' reply
- Surveillance of patients with thin melanoma.
- Contemporary management of locoregionally advanced melanoma in Australia and New Zealand and the role of adjuvant systemic therapy.
- Deep Learning for Basal Cell Carcinoma Detection for Reflectance Confocal Microscopy.
- Histological regression in melanoma: impact on sentinel lymph node status and survival.
- Knowledge, views and expectations for cancer polygenic risk testing in clinical practice: a cross-sectional survey of health professionals.
- Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers.
- Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules.
- Melanoma In Situ: A Critical Review and Re-Evaluation of Current Excision Margin Recommendations.
- A multicentre study of naevus-associated melanoma vs. de novo melanoma, tumour thickness and body site differences.
- Characterizing the Clinical Implications of Histologic Regression in Melanoma Requires Clear Diagnostic Criteria That Are Consistently Applied-Reply.
- Clinical and Molecular Heterogeneity in Patients with Innate Resistance to Anti-PD-1 +/- Anti-CTLA-4 Immunotherapy in Metastatic Melanoma Reveals Distinct Therapeutic Targets.
- Hyperacute toxicity with combination ipilimumab and anti-PD1 immunotherapy.
- Risk of radiation necrosis after stereotactic radiosurgery for melanoma brain metastasis by anatomical location.
- Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers.
- Bilateral facial neuritis associated with dabrafenib and trametinib after failure of neoadjuvant immunotherapy for stage III melanoma.
- Re-defining the role of surgery in the management of patients with oligometastatic stage IV melanoma in the era of effective systemic therapies.
- Role of Tumor-Infiltrating B Cells in Clinical Outcome of Patients with Melanoma Treated With Dabrafenib Plus Trametinib
- PDCD1 Polymorphisms May Predict Response to Anti-PD-1 Blockade in Patients With Metastatic Melanoma.
- Identifying the 'Active Ingredients' of an Effective Psychological Intervention to Reduce Fear of Cancer Recurrence: A Process Evaluation.
- Evolutionary predictability of genetic versus nongenetic resistance to anticancer drugs in melanoma.
- Neoadjuvant Immunotherapy in Melanoma – The New Frontier
- Neoadjuvant immunotherapy in melanoma - the new frontier
- Evaluation of Crizotinib Treatment in a Patient With Unresectable GOPC-ROS1 Fusion Agminated Spitz Nevi
- Counting mitoses: SI(ze) matters!
- Melanoma with osseous or chondroid differentiation: a report of eight cases including SATB2 expression and mutation analysis.
- Risk factors for melanoma by anatomical site: an evaluation of aetiological heterogeneity.
- Current Challenges in Access to Melanoma Care: A Multidisciplinary Perspective.
- Validation of the American Joint Committee on Cancer Staging in Squamous Cell Carcinoma of the Vermilion Lip
- Immunotherapy in advanced Merkel cell carcinoma: Sydney west cancer network experience.
- Predicting recurrence in patients with sentinel node-negative melanoma: validation of the EORTC nomogram using population-based data.
- Melanoma Cell State-Specific Responses to TNFα
- An independent external validation of melanoma risk prediction models using the Australian Melanoma Family Study.
- Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
- Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC)
- Melanoma recurrence patterns and management after adjuvant targeted therapy: a multicentre analysis.
- Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy
Events
Portfolio
Academic Authors
- Long, Georgina
- Scolyer, Richard
- van Akkooi, Alexander
- Carlino, Matteo
- Ch'ng, Sydney
- Cust, Anne
- Ferguson, Peter
- Guitera, Pascale
- Hersey, Peter
- Hong, Angela
- Kefford, Rick
- Lo, Serigne
- Mann, Graham
- Martin, Linda
- Menzies, Alex
- Morton, Rachael
- Nieweg, Omgo
- Pires da Silva, Ines
- Pennington, Tom
- Rawson, Robert
- Rizos, Helen
- Rtshiladze, Michael
- Saw, Robyn
- Shannon, Kerwin
- Spillane, Andrew
- Stretch, Jonathan
- Thompson, John
- Varey, Alex
- Wilmott, James
Page load link
